Welcome to our dedicated page for Therapeuticsmd news (Ticker: TXMD), a resource for investors and traders seeking the latest updates and insights on Therapeuticsmd stock.
TherapeuticsMD Inc (TXMD) is an innovative pharmaceutical company focused on advancing women's health through specialized therapies and strategic licensing partnerships. This page serves as the definitive source for all official company announcements, regulatory updates, and market developments.
Investors and industry professionals will find timely updates on TXMD's prescription products including IMVEXXY, BIJUVA, and ANNOVERA, along with financial disclosures and partnership agreements. Our curated news feed covers essential developments including FDA milestones, licensing expansions with commercial partners like Mayne Pharma, and clinical research advancements.
Key updates include earnings reports, product pipeline progress, intellectual property developments, and strategic initiatives in the women's healthcare sector. All content is verified through primary sources to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for direct access to TherapeuticsMD's latest press releases and objective news coverage. Check regularly for updates on pharmaceutical royalties, regulatory decisions, and market positioning within the competitive women's health landscape.
TherapeuticsMD, Inc. (NASDAQ: TXMD) is recognizing Menopause Awareness Month to empower the 64 million U.S. women currently in menopause. With over 80% experiencing symptoms, the company highlights vulvar and vaginal atrophy (VVA), affecting more than half of menopausal women. The 'Take Pause' initiative includes educational videos featuring Dr. Rebecca Brightman to raise awareness about VVA and available treatments such as IMVEXXY. This effort aims to normalize discussions around menopause and its symptoms, encouraging women to seek care.
TherapeuticsMD (NASDAQ: TXMD) announced that CMS confirmed a permanent product-specific HCPCS J Code for ANNOVERA, effective October 1, 2021. This new coding will enable Title X Family Planning clinics to gain reimbursement for dispensing ANNOVERA, streamlining billing processes for approximately 4,900 facilities. The J Code is unique to ANNOVERA, enhancing patient access to the only yearly, patient-controlled vaginal contraceptive in the market. This development reflects a push towards improving women's healthcare accessibility.
TherapeuticsMD, Inc. (NASDAQ: TXMD) announced the appointment of Hugh O’Dowd as President, succeeding John C.K. Milligan, IV, now CEO of vitaCare Prescription Services. O’Dowd brings over 20 years of experience, notably at Novartis, and aims to enhance the company's value and commercialization efforts in women's health. The company also plans to grant O’Dowd 2.75 million RSUs and PSUs as part of his inducement. The management change reflects a strategic move to strengthen leadership in advancing TherapeuticsMD's portfolio.
TherapeuticsMD (TXMD) reported second-quarter 2021 financial results, highlighting a strong growth in net product revenues amounting to $23 million, up from $10.7 million in Q2 2020. Key products ANNOVERA and IMVEXXY saw substantial revenue increases of 202% and 56%, respectively. The company also noted progress in prescription growth and access to telemedicine. Despite a net loss of $42.7 million, up from $39.4 million in Q1 2021, cash on hand rose to $111.4 million. The firm is exploring investment opportunities in vitaCare, aiming for non-dilutive capital options.
TherapeuticsMD, a leader in women's healthcare, is set to announce its Q2 2021 financial results on August 4, 2021, before U.S. markets open. The executive team will host a conference call at 8:30 a.m. ET for a financial review and business update. Interested parties can access the call via U.S. and international lines or through a live webcast at therapeuticsmd.com. The event will also be archived for 30 days for replay. TherapeuticsMD is focused on advancing women's health through innovative products.
TherapeuticsMD, Inc. (NASDAQ: TXMD) announced the submission of a supplemental New Drug Application (sNDA) for low-dose BIJUVA (estradiol and progesterone) capsules to the FDA. The company anticipates receiving acceptance notification within approximately 74 days, with a potential review period of ten months. BIJUVA is already approved for moderate to severe vasomotor symptoms due to menopause. The CEO expressed optimism about the new dosage providing additional therapeutic options for women.
TherapeuticsMD, Inc. (NASDAQ: TXMD) reported a 60% increase in net product revenue for Q1 2021, totaling $19.6 million, compared to Q1 2020. The performance was driven by strong sales of ANNOVERA, which saw revenues rise to $8.8 million, and BIJUVA, which grew by 120% to $2.5 million. The company also secured three new patents for ANNOVERA, extending exclusivity to June 2039. Despite a 13% decline in revenue from Q4 2020, the overall outlook remains positive with a continuous improvement in financial performance.
TherapeuticsMD (NASDAQ: TXMD) has presented Phase 3 data for ANNOVERA, its FDA-approved contraceptive, showcasing favorable menstrual bleeding profiles at the 2021 ACOG Annual Meeting. The analysis included data from 2,070 women over 453,622 patient-days, indicating 94.8% to 97.6% reported no unscheduled bleeding across 13 cycles. Discontinuation due to bleeding-related issues was under 2%. ANNOVERA offers a long-lasting, patient-controlled contraceptive option but comes with significant risk warnings, particularly for women over 35 who smoke.
TherapeuticsMD, Inc. (NASDAQ: TXMD), a leader in women’s healthcare, will report Q1 2021 financial results on May 6, 2021, before U.S. market opening. Following this, an executive management conference call and webcast is scheduled for 8:30 a.m. ET to discuss the results and provide a business update. Investors can access the call via telephone or through a live audio webcast on the company's website. Replays will be available for 30 days. TherapeuticsMD specializes in products for family planning, reproductive health, and menopause management.
FAQ
What is the current stock price of Therapeuticsmd (TXMD)?
What is the market cap of Therapeuticsmd (TXMD)?
